Everything below concerns epithalamin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-29. Numbers and descriptions here follow the published literature rather than marketing material.
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic tetrapeptide | Four amino acid residues |
| Residue sequence | Ala-Glu-Asp-Gly | Abbreviated AEDG |
| Approximate mass | 390.35 Da | Monoisotopic, free base form |
| Parent preparation | Epithalamin extract | Derived from pineal tissue |
| Common spelling variants | Epithalon, epithalone, AEDG | Affects literature retrieval |
In its supplied form epitalon is a white to off-white powder, usually lyophilized and often hygroscopic. It dissolves readily in water and in aqueous buffers, and it is commonly handled as the acetate or trifluoroacetate salt to improve stability during purification and drying. The amide backbone is labile in aqueous media, so solutions are less durable than the dry solid. Handling notes in the chemical literature therefore emphasize keeping the powder dry, cool and shielded from light until it is dissolved.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.
Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.
Peptides of this size are generally stable as dry solids but degrade in solution over time. The principal routes are hydrolysis of the peptide backbone and oxidation, with hydrolysis favoured by elevated temperature and extreme pH. Aqueous solutions held at room temperature can show measurable loss of purity within days, while frozen aliquots are considerably more durable. Because the sequence contains neither cysteine nor methionine, oxidation is less of a concern than for many other peptides, but pH control during handling still matters.
Storage recommendations center on limiting moisture, heat, and light. The dry powder is generally kept at minus 20 degrees Celsius, and some suppliers recommend minus 80 degrees for long-term archival. Once dissolved, solutions are usually aliquoted and frozen to avoid repeated freeze-thaw cycles, which can promote aggregation or degradation. Aqueous stability depends on pH and concentration, and buffered saline is often preferred over plain water for biological work. Stability data specific to epitalon remain limited, so general peptide-handling practices are applied by analogy rather than from product-specific validation.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and its calculated monoisotopic mass is approximately 390.35 daltons. The compound does not occur naturally as a free peptide; it is produced by solid-phase peptide synthesis. Because it contains two acidic residues and no basic residues, the neutral form carries a net negative charge at physiological pH. This charge profile influences how the peptide behaves in solution and during chromatographic analysis.
Laboratory-grade epitalon is typically supplied as a lyophilized powder. Purity is commonly assessed with reverse-phase high-performance liquid chromatography, often paired with mass spectrometry to confirm molecular identity. Amino acid analysis and peptide mapping can provide additional confirmation of sequence. Certificates of analysis for research materials frequently report purity above 95 percent, although the methods behind such figures vary between suppliers. The absence of a pharmacopeial monograph means that no single standardized assay defines the compound, so reported results depend on the analytical protocol chosen.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Many P-51s were sold as surplus after the war, often for as little as $1,500. Some were sold to former wartime fliers or other aficionados for personal use, while others were modified for air racing. One of the most significant Mustangs involved in air racing was serial number 44-10947, a surplus P-51C-10-NT purchased by film stunt pilot Paul Mantz. He modified the wings, sealing them to create a giant fuel tank in each one; these "wet wings" reduced the need for fuel stops or drag-inducing drop tanks. Named Blaze of Noon after the film Blaze of Noon, the aircraft won the 1946 and 1947 Bendix Air Races, took second in the 1948 Bendix, and placed third in the 1949 Bendix. Mantz also set a US coast-to-coast record in 1947. He sold the Mustang to Charles F. Blair Jr (future husband of Maureen O'Hara), who renamed it Excalibur III and used it to set a New York-to-London (about 3,460 miles or 5,570 kilometres) record in 1951: 7 hr 48 min from takeoff at Idlewild to overhead London Airport. Later that year, Blair flew from Norway to Fairbanks, Alaska, via the North Pole (about 3,130 miles or 5,040 kilometres), proving that navigation via sun sights was possible over the magnetic North Pole region. For this feat, he was awarded the Harmon Trophy and the Air Force was forced to change its thoughts on a possible Soviet air strike from the north. This Mustang now sits in the National Air and Space Museum's Steven F. Udvar-Hazy Center.
==== MeSH D12.125.740 – phosphoamino acids ==== MeSH D12.125.740.025 – 2-amino-5-phosphonovalerate MeSH D12.125.740.675 – phosphocreatine MeSH D12.125.740.700 – phosphoserine MeSH D12.125.740.725 – phosphothreonine MeSH D12.125.740.740 – phosphotyrosine
== Biocultural bioarchaeology == The study of human remains can illuminate the relationship between physical bodies and socio-cultural conditions and practices, via a biocultural bioarchaeology model. Bioarchaeology is typically regarded as a positivist, science-based discipline, while the social sciences are regarded as constructivist. Bioarchaeology has been criticized for having little to no concern for culture or history. One scholar argued that scientific/forensic scholarship ignores cultural/historic factors. He proposed that a biocultural version of bioarchaeology offered a more meaningful, nuanced, and relevant picture, especially for descent populations. Biocultural bioarchaeology combines standard forensic techniques with investigations of demography and epidemiology in order to assess socioeconomic conditions experienced by human communities. For example, incorporation of analysis of grave goods can further the understanding of daily activities. Some bioarchaeologists view the discipline as a crucial interface between the science and the humanities; as the human body is made and re-made by both biological and cultural factors. Another type of bioarchaeology focuses on quality of life, lifestyle, behavior, biological relatedness, and population history. It does not closely link skeletal remains to their archaeological context, and may best be viewed as a "skeletal biology of the past". Inequalities exist in all human societies.
=== Osteonecrosis of the jaw after use of Fosamax === Fosamax (alendronate) is a bisphosphonate used for the treatment of post-menopausal osteoporosis and for the prevention of skeletal problems in certain cancers. The American College of Clinical Endocrinology, the American College of Obstetricians and Gynecologists, the North American Menopause Society and the UK National Osteoporosis Guideline Group recommend alendronate and certain other bisphosphonates as first line treatments for post-menopausal osteopotosis. Long-term treatment with bisphosponates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment. Alendronate reduces the risk of hip, vertebral, and wrist fractures by 35-39%. In December 2013, Merck agreed to pay a total of $27.7 million to 1,200 plaintiffs in a class action lawsuit alleging that the company's osteoporosis drug had caused them to develop osteonecrosis of the jaw. Prior to the settlement, Merck had prevailed in 3 of 5 so-called bellwether trials. Approximately 4,000 cases still await adjudication or settlement as of August 2014. There have also been thousands of lawsuits alleging that Fosamax increased the risk of thigh-bone fractures. In March 2022, Merck defeated approximately 500 lawsuits over Fosamax in New Jersey when U.S. District Judge Freda L. Wolfson ruled that the plaintiffs' lawsuit was preempted by federal law.
Sources: en.wikipedia.org
=== Synonymous mutation of bases === When an incorrect nucleotide is inserted during replication or transcription of a coding region, it can affect the eventual translation of the sequence into amino acids. Since multiple codons are used for the same amino acids, a change in a single base may still lead to translation of the same amino acid. This phenomenon is referred to as degeneracy and allows for a variety of codon combinations leading to the same amino acid being produced. For example, the codes TCT, TCC, TCA, TCG, AGT, and AGC all code for the amino acid serine. This can be explained by the wobble concept. Francis Crick proposed this theory to explain why specific tRNA molecules could recognize multiple codons. The area of the tRNA that recognizes the codon called the anticodon is able to bind multiple interchangeable bases at its 5' end due to its spatial freedom. A fifth base called inosine can also be substituted on a tRNA and is able to bind with A, U, or C. This flexibility allows for changes in bases in codons leading to translation of the same amino acid. The changing of a base in a codon without the changing of the translated amino acid is called a synonymous mutation. Since the amino acid translated remains the same a synonymous mutation has traditionally been considered a neutral mutation. Some research has suggested that there is bias in selection of base substitution in synonymous mutation. This could be due to selective pressure to improve translation efficiency associated with the most available tRNAs or simply mutational bias.
== History == Polymer Char was founded by B. Monrabal in 1992 in the Valencia Technology Park, in Spain, being registered with the name of Polymer Characterization, S.A. Its initial goal was to develop a commercial Crystallization Analysis Fractionation (CRYSTAF) instrument based on technology developed by Monrabal at Dow Chemical Company laboratories in the Netherlands to measure chemical composition distribution in semicrystalline polymers. A CRYSTAF prototype was presented at Pittcon in 1994. The first product was acquired in 1995 by a petrochemical company in South Korea. The company has also developed techniques and instruments for polymer characterization, and more specifically, for polyolefin (polyethylene and polypropylene) characterization. Polymer Char's technology is present in the petrochemical and research and development industries in over 20 countries in North America, South America, Europe, Africa, and Asia.
=== Lifespan === In the East China Sea, blue mackerel spawn between February and May, when the water temperatures are ideal. In New South Wales, most spawning occurs 10 km (6.2 mi) offshore in waters 100–125 m (328–410 ft) in depth. The East Australian Current can carry eggs and larvae away from the original spawning grounds, broadening the area in which blue mackerel are located. However, egg and larvae probability of surviving decreases the further they are carried by the current. A mature blue mackerel is considered to be over 31 cm (12 in) long. Mackerel can live up to 7 years and grow up to 50 cm (20 in) in length, but are most commonly found to be between 1 and 3 years of age. Counting the marks on otoliths is used to determine the age of blue mackerel.
=== Transmitter === The transmitter is the component of the Dexcom CGM system that is responsible for sending glucose data from the sensor to a compatible receiver, smartphone, or other monitoring device via Bluetooth, allowing users to view real-time glucose readings. Throughout previous iterations of the Dexcom CGM, the transmitter has typically been shaped like a pear. The Dexcom G7 and Stelo models feature a smaller, rounder design and integrate the sensor and transmitter into a single, disposable system.
=== Zinc toxicity === Increased zinc consumption is another cause of copper deficiency. Zinc is often used for the prevention or treatment of common colds and sinusitis (inflammation of sinuses due to an infection), ulcers, sickle cell disease, celiac disease, memory impairment, and acne. Zinc is found in many common vitamin supplements and is also found in denture creams. Recently, several cases of copper deficiency myeloneuropathy were found to be caused by prolonged use of denture creams containing high quantities of zinc. Metallic zinc is the core of all United States currency coins, including copper-coated pennies. People who ingest many coins will have elevated zinc levels, leading to zinc-toxicity-induced copper deficiency and the associated neurological symptoms. This was the case for a 57-year-old woman diagnosed with schizophrenia. The woman consumed over 600 coins and started to show neurological symptoms such as unsteady gait and mild ataxia.
Sources: en.wikipedia.org
It is based on epithalamin, a peptide-rich preparation obtained from pineal gland tissue and studied in the former Soviet Union. Researchers later identified the tetrapeptide AEDG as a constituent fragment of that material. Modern supplies are produced by chemical synthesis rather than tissue extraction.
No. Epithalamin is a heterogeneous extract containing many peptides, while epitalon is a single synthesised tetrapeptide. Publications sometimes treat findings from the two as equivalent, which is a common source of confusion. Their compositions differ and they are not interchangeable in analytical terms.
Most published work uses cell cultures or rodents because those models are faster and less costly to run. The few human trials that have been reported are small, and several lack control groups or blinding. This restricts what can reasonably be concluded about effects in people.
Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.